Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Open access

Abstract

PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. METHODS: In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). RESULTS: After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. CONCLUSIONS: With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-018-05125-4

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 a Investigator-assessed progression-free survival (ITT population). b Forest plot of investigator-assessed PFS overall and across subgroups (ITT population). BICR blinded independent central review, ECOG PS Eastern Cooperative Oncology Group performance status, ET endocrine therapy, HR hazard ratio, IA investigator assessed, ITT intent-to-treat, LET letrozole, PFS progression-free survival, NE not estimable, NR not reached, PAL palbociclib, PBO placebo, TFI treatment-free interval. a: 1-sided P value from the log-rank test. b: Per tumor site. c: Protocol-defined disease-free interval is equivalent to TFI in this analysis and refers to TFI since completion of prior (neo)adjuvant therapy and onset of metastatic disease or disease recurrence. d: A few patients initially enrolled as having measurable disease were later found to have non-measurable disease beyond bone-only disease
Fig. 1 a Investigator-assessed progression-free survival (ITT population). b Forest plot of investigator-assessed PFS overall and across subgroups (ITT population). BICR blinded independent central review, ECOG PS Eastern Cooperative Oncology Group performance status, ET endocrine therapy, HR hazard ratio, IA investigator assessed, ITT intent-to-treat, LET letrozole, PFS progression-free survival, NE not estimable, NR not reached, PAL palbociclib, PBO placebo, TFI treatment-free interval. a: 1-sided P value from the log-rank test. b: Per tumor site. c: Protocol-defined disease-free interval is equivalent to TFI in this analysis and refers to TFI since completion of prior (neo)adjuvant therapy and onset of metastatic disease or disease recurrence. d: A few patients initially enrolled as having measurable disease were later found to have non-measurable disease beyond bone-only diseaseCC BY · PubMed Central
Fig. 2 Investigator-assessed PFS in subgroups of patients (ITT population). Kaplan–Meier curves for a bone-only and b single disease site—both representing low disease burden—and c no prior endocrine therapy with non-visceral disease. HR hazard ratio, ITT intent-to-treat, NE not estimable, PFS progression-free survival
Fig. 2 Investigator-assessed PFS in subgroups of patients (ITT population). Kaplan–Meier curves for a bone-only and b single disease site—both representing low disease burden—and c no prior endocrine therapy with non-visceral disease. HR hazard ratio, ITT intent-to-treat, NE not estimable, PFS progression-free survivalCC BY · PubMed Central
Fig. 3 Kaplan–Meier estimates of time to initiation of subsequent systemic anticancer therapies (anticancer treatment included any anticancer related systemic therapy and surgery for the disease under study) (ITT population) a Time from randomization to first subsequent therapy. b Time from randomization to second subsequent therapy (if the difference in time to initiation of the second subsequent therapy between the 2 treatment arms was shortened compared with the difference between the median PFS values, it may suggest that the treatment benefit of the first subsequent therapy was compromised. If the difference was similar, it suggests no compromise regarding the efficacy of the first subsequent therapy). c Time from randomization to first subsequent chemotherapy. EFS event-free survival, ITT intent-to-treat
Fig. 3 Kaplan–Meier estimates of time to initiation of subsequent systemic anticancer therapies (anticancer treatment included any anticancer related systemic therapy and surgery for the disease under study) (ITT population) a Time from randomization to first subsequent therapy. b Time from randomization to second subsequent therapy (if the difference in time to initiation of the second subsequent therapy between the 2 treatment arms was shortened compared with the difference between the median PFS values, it may suggest that the treatment benefit of the first subsequent therapy was compromised. If the difference was similar, it suggests no compromise regarding the efficacy of the first subsequent therapy). c Time from randomization to first subsequent chemotherapy. EFS event-free survival, ITT intent-to-treatCC BY · PubMed Central
Fig. 4 Between-treatment comparison of changes from baseline for FACT-B scores (PRO analysis set included patients in the PRO-evaluable population [i.e., patients with a baseline and ≥ 1 postbaseline assessment before the end of the study treatment]) a FACT-B scales of overall scores. b FACT-B total score by subgroups. BC breast cancer, ECOG PS Eastern Cooperative Oncology Group performance status, FACT-B Functional Assessment of Cancer Therapy-Breast, FACT-G Functional Assessment of Cancer Therapy-General, LET letrozole, PAL palbociclib, PBO placebo, PRO patient-reported outcome, TFI treatment-free interval, TOI Trial Outcome Index
Fig. 4 Between-treatment comparison of changes from baseline for FACT-B scores (PRO analysis set included patients in the PRO-evaluable population [i.e., patients with a baseline and ≥ 1 postbaseline assessment before the end of the study treatment]) a FACT-B scales of overall scores. b FACT-B total score by subgroups. BC breast cancer, ECOG PS Eastern Cooperative Oncology Group performance status, FACT-B Functional Assessment of Cancer Therapy-Breast, FACT-G Functional Assessment of Cancer Therapy-General, LET letrozole, PAL palbociclib, PBO placebo, PRO patient-reported outcome, TFI treatment-free interval, TOI Trial Outcome IndexCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 1

  1. IBRANCE® (palbociclib) (2018) Full prescribing information. Pfizer Inc, New York

Cited by

See all 480

Metadata

Authors
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. H., Gelmon, K. A., & Slamon, D. J.
Affiliations
  • University of California, San Francisco (US)
  • University of California, Los Angeles (US)
  • TUM Klinikum (DE)
  • Republican Oncological Clinical Dispensary (RU)
  • University of Alberta (CA)
  • LMU Klinikum (DE)
  • Pfizer (United States) (US)
  • Pfizer (Italy) (IT)
  • BC Cancer Agency (CA)
Corresponding author
Rugo, H. S.
Venue
Breast Cancer Research and Treatment
Published
2019-01-10
Volume
174
Issue
3
Pages
719-729
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W2908699784
Cited by
443
References
19
Citations by year
2026: 39 · 2025: 68 · 2024: 71 · 2023: 67 · 2022: 59 · 2021: 67 · 2020: 51 · 2019: 21
FWCI
36.37
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • mediaTUM (Technical University of Munich) (submittedVersion, other-oa)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
palbociclib, letrozole, estrogen receptor-positive breast cancer, HER2-negative breast cancer, advanced breast cancer, first-line therapy, progression-free survival, patient-reported outcomes, quality of life, CDK4/6 inhibitors, endocrine therapy, subgroup analysis
MeSH terms
Letrozole, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Piperazines, Pyridines, Quality of Life, Receptors, Estrogen, Treatment Outcome, Postmenopause, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. https://app.cochat.ai/papers/10.1007/s10549-018-05125-4
The paper
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., Mori, A., Gauthier, E. R., Bartlett, C. H., Gelmon, K. A., & Slamon, D. J. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-018-05125-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.